

Biophytis to present preclinical proof of concept for Sarcob to treat sarcopenic obesity at SCWD on December 4th

- **Poster presentation elucidates SARCOB's mechanism of action**
- **Preclinical data support ongoing preparation for Phase IIb testing**

Paris (France) & Cambridge (Mass), 26 November 2015 – Biophytis (Alternext Paris : ALBPS), a geriatric medicine company advancing clinical stage drug-candidates to treat sarcopenic obesity and age related macular degeneration (AMD), today announced that it will present preclinical data supporting the use of its lead therapeutic candidate Sarcob (BIO101), which will be in mid-stage clinical testing next year, in a poster presentation at the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) being held this year in Paris from 4 to 6 December.

“Sarcopenic obesity is a pathology that is increasingly common in our aging population, yet without therapeutic treatment,” said Stanislas Veillet, CEO of Biophytis. “So, we are honored to present to the international scientific community, especially the key opinion leaders in muscular dystrophies, the novel mechanism of action of our clinical stage therapeutic candidate for this debilitating disease, Sarcob. This orally available small molecule activator of MAS receptor modulates the renin-angiotensin system, a pathway that plays a central role in aging – and degeneration – of muscles, whereby the size of the fibers is shortened, a process accelerated by obesity.”

Sarcob drug candidates are orally available selective MAS receptor agonists, which have demonstrated preclinical proof of concept – specifically the anabolic growth of muscle (i.e. increased muscle fiber diameter, increased protein density and inhibition of myostatin) – in models of sarcopenic obesity. Preparations for mid-stage (Phase IIb) clinical testing are ongoing. To learn more, please visit:

<http://www.biophytis.com/en/pipeline/plateforme-sarcob/>

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. In addition to Sarcob, the company is advancing Maculia (BIO201) to treat dry age-related macular degeneration (AMD) into mid-stage (Phase IIb) clinical testing next year.

The company was founded in partnership with researchers at the UPMC (Pierre et Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.

BIOPHYTIS is eligible for the French PEA-PME regime.

Biophytis
Stanislas Veillet
CEO
contact@biophytis.com
Tel : +33 1 41 83 66 00

Milestones
Bruno Arabian
barabian@milestones.fr
Tel : +33 1 83 62 34 84
Mob : +33 6 87 88 47 26

LifeSci Advisors
Chris Maggos
Managing Director, Europe
chris@lifesciadvisors.com
Tel : +41 79 367 6254